Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
J Neurointerv Surg. 2013 Nov;5(6):562-5. doi: 10.1136/neurintsurg-2012-010460. Epub 2012 Nov 6.
Onyx is a liquid non-adhesive viscous embolic agent ideal for slow targeted injections which is currently approved for the treatment of intracranial aneurysms and arteriovenous malformations.
We performed a single-center retrospective analysis of consecutive patients who underwent off-label use of Onyx as the single embolic agent for the treatment of traumatic or infectious pseudoaneurysms involving the cerebral or cranial vasculature.
A total of nine pseudoaneurysms treated by Onyx embolization were identified. Six of the pseudoaneurysms were post-surgical, one of the pseudoaneurysms was traumatic and two were infectious in nature. The mean pseudoaneurysm size was 5.9 mm (range 2-10 mm). Onyx-34 was used in all cases. Following treatment there was complete exclusion of all pseudoaneurysms including their inflow and outflow zones.
Our experience demonstrates the efficacy and applicability of the use of Onyx in the treatment of complex traumatic and mycotic pseudoaneurysms involving the cerebral and cranial vascular tree.
Onyx 是一种液体非粘性粘性栓塞剂,非常适合缓慢靶向注射,目前已被批准用于治疗颅内动脉瘤和动静脉畸形。
我们对连续接受 Onyx 作为单一栓塞剂治疗涉及脑或颅脑血管的创伤性或感染性假性动脉瘤的患者进行了单中心回顾性分析。
共确定了 9 个经 Onyx 栓塞治疗的假性动脉瘤。6 个假性动脉瘤是手术后的,1 个是创伤性的,2 个是感染性的。假性动脉瘤的平均大小为 5.9 毫米(范围 2-10 毫米)。所有病例均使用 Onyx-34。治疗后,所有假性动脉瘤及其流入和流出区均完全闭塞。
我们的经验表明,Onyx 在治疗涉及脑和颅脑血管树的复杂创伤性和真菌性假性动脉瘤方面具有疗效和适用性。